This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti‐drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD): 735. (October 2017)
Record Type:
Journal Article
Title:
Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti‐drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD): 735. (October 2017)
Main Title:
Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti‐drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD)